TOPOSAR Drug Patent Profile
✉ Email this page to a colleague
When do Toposar patents expire, and what generic alternatives are available?
Toposar is a drug marketed by Teva Parenteral and is included in one NDA.
The generic ingredient in TOPOSAR is etoposide. There are eleven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the etoposide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Toposar
A generic version of TOPOSAR was approved as etoposide by HIKMA on July 17th, 1995.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TOPOSAR?
- What are the global sales for TOPOSAR?
- What is Average Wholesale Price for TOPOSAR?
Summary for TOPOSAR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 90 |
| Clinical Trials: | 146 |
| Patent Applications: | 2,711 |
| Drug Prices: | Drug price information for TOPOSAR |
| DailyMed Link: | TOPOSAR at DailyMed |
Recent Clinical Trials for TOPOSAR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of California, San Francisco | Phase 2 |
| RenJi Hospital | Phase 2 |
| Incyte Corporation | Phase 2 |
US Patents and Regulatory Information for TOPOSAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Parenteral | TOPOSAR | etoposide | INJECTABLE;INJECTION | 074166-001 | Feb 27, 1995 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
